Related Experiment Video
Updated: Feb 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Adherence to Disease Modifying Anti Rheumatic Drugs in Tunisian patients with Juvenile Idiopathic Arthritis: An
Alia Fazaa1,2, Asma Selmi3, Azza Saad1
1University hospital, Mongi Slim, Department of Rheumatology, 2046 La Marsa, Tunisia.
Introduction:
Non-adherence or poor therapeutic adherence appears to be particularly prevalent in chronic inflammatory rheumatism, notably in Juvenile Idiopathic Arthritis (JIA). It reduces therapeutic efficacy, accelerates disease progression, and poses a significant public health and economic challenge.
Aim:
To evaluate adherence to disease-modifying treatments in Tunisian patients with JIA and to identify factors influencing therapeutic adherence.
Methods:
This cross-sectional study included patients with JIA (defined by ILAR criteria) who had been undergoing treatment with conventional synthetic (csDMARDs) and/or biologic (bDMARDs) disease-modifying anti-rheumatic drugs for at least three months. Socio-demographic, clinical, biological, radiological, and therapeutic data were collected. Therapeutic adherence was assessed using two methods: self-reported adherence by patients and their parents, and adherence measured via the Parent Adherence Report Questionnaire (PARQ) and the Child Adherence Report Questionnaire (CARQ).
Results:
A total of 30 patients (16 girls, 14 boys) with a mean age of 24.8 ± 11 years [8-47] were included. csDMARDs were prescribed for 76.7% of patients while 26.7% received bDMARDs. Self-reported adherence was 80% among parents and 76.7% among patients. Mean adherence scores were 74.58 ± 36 [0-100] on the PARQ and 74 ± 34 [0-100] on the CARQ. Univariate analysis revealed that adherence measured by the PARQ was positively correlated with erythrocyte sedimentation rate (ESR) (p=0.001; r=0.643) and C-reactive protein (CRP) (p=0.008; r=0.561) and negatively correlated with maternal age (p=0.005; r=-0.572), difficulty in medication administration reported by the parent (p0.0001; r=-0.698), and negative reactions to medication reported by both the patient (p=0.012; r=-0.506) and the parent (p=0.001; r=-0.651). Adherence measured by the CARQ was significantly associated with indigent health insurance status (p=0.019). In multivariate analysis, predictors of non-adherence on the PARQ included advanced maternal age (p=0.004), low ESR (p=0.029), and negative reactions to medications (p0.0001). On the CARQ, difficulty in adhering to the treatment regimen (p=0.042) was the only significant predictor.
Conclusion:
This study demonstrates good therapeutic adherence among Tunisian patients with JIA. Predictors of non-adherence included advanced maternal age, low disease activity, negative reactions to medications, and difficulties in following treatment regimens. Educational strategies targeting these factors may improve adherence and enhance patient outcomes.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors
Rheumatic Heart Disease I: Introduction

